Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Investor Presentation (April 2020)
11 slides from Little Green Pharma's investor presentation, Apr 30, 2020
Slide 1: Investor Presentation
Investor Presentation April 2020
Slide 2: Disclaimer
Disclaimer NOT AN OFFER OF SECURITIES Forward looking statement Not financial product advice This document has been independently prepared by Little Green Pharma Ltd Certain information in this document refers to the intentions of This document does not constitute financial product advice ACN 615 58
Slide 3: Why LGP
Why LGP Company Highlights Generating revenue - month on month increase First company to export Australian medicinal cannabis products Manufacturing partner - EU-GMP recognised Expanded cultivation facility enabling production capacity up to 110,000 bottles p/a Construction of own manufacturing faci
Slide 4: Company Overview
Company Overview Little Green Pharma is a leading vertically integrated medicinal cannabis business 1 with existing sales and a clear pathway to increasing margins & driving significant revenue growth in domestic & European markets Vertically integrated Expansion of cultivation facility Strong in-ma
Slide 5: Our Business Model Captures Value
Our Business Model Captures Value Integrated model captures the medicinal cannabis value chain Cultivation & Manufacturing Education Distribution IP and R&D Production Programs Cultivation Exclusive 5-year Strong in-market brand, Multiple 18-month selling capacity to agreement currently selling four
Slide 6: We have a track record of growing patient access
We have a track record of growing patient access Strong growth in sales and patients using LGP products in Australia 3,1750+ Patients have used LGP’s products in Australia 1. CMGR = Compound Monthly Growth Rate, since January 2019 Unique Patients Using LGP Products (RHS) LGP Cumulative Bottle Sold (
Slide 7: Our financial & operational metrics on a positive growth trend
Our financial & operational metrics on a positive growth trend Significant operational momentum Revenue (H1FY20) Gross Margin (H1FY20) Biological Assets (H1FY20) Up 188% to $716,000 54%1, up from 41% Up 30% to $667,570 for 6 months vs. 12 months to FY19 vs. FY19 vs. end FY19 Patients (to 31 Mar 2020
Slide 8: We have made solid progress since ASX listing
We have made solid progress since ASX listing LGP has made considerable commercial progress since October 2019 Executed EU Sales Licence & Partnerships Product Agreements Facility 3-year sales agreement Granted expansion Supply agreement New product signed with DEMECAN to Medicinal Cannabis for rese
Slide 9: News Flow
News Flow Significant news flow as LGP executes growth strategy Completion of cultivation facility expansion First product delivered to Astral Health in the UK Further expansion of product line with new LGP Classic CBD 50 product Final permit granted and first crop planting at expanded facility Firs
Slide 10: Corporate Overview
Corporate Overview Snapshot Shareholders1 Shareholding Ownership • Listed on the ASX on 20 February 2020 Elixxer Ltd. 30.8m 23.1% Fleta Solomon 19.6m 14.7% • Raised $10 million at IPO Angus Caithness 5.5m 4.1% GSCO - ECA Resource Geologic Partners 5.4m 4.0% • No debt TIGA Trading Pty Ltd, Asset Mana
Slide 11: Gre
yt Gre
Little Green Pharma — Investor Presentation (April 2020) on 6ix